ANGIOGENE PHARMACEUTICALS

Angiogene Pharmaceuticals Ltd., a drug discovery company, engages in developing drug candidates for the treatment of cancer and other angiogenic diseases. It develops compounds to the preclinical stage and at that point licenses to pharmaceutical and drug development companies. The company also carries out research activities on contract basis. Its product pipeline includes ZD6126, a vascular disrupting agent that acts via tubulin depolymerization; MN029, a tubulin-binding vascular disrupting agent; ANG500, a series of compounds with activity against tumour models; and ANG700, a series of hypoxia activated prodrugs. Angiogene Pharmaceuticals Ltd.